# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Louis (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX002-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desmond Achterberg-Cole, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Louis is a 55-year-old man with cocaine use disorder and a cocaine-induced psychotic disorder now in remission on aripiprazole, and stage 2 hypertension on amlodipine, who comes for his yearly preventive visit one week before his ten-week review. The persecutory fears have not returned, and he sleeps six to seven hours. Two weeks ago, after an evening with an old acquaintance, he used cocaine on one day; he told the contingency management counselor at his next urine test, which was positive, and has not used since. His home blood pressure readings average 132/84. He has had no chest pain. He cannot recall a colon cancer screening test or any vaccines since his Army years. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 55 |
| Cocaine | One day of use two weeks ago, reported by him; none since |
| Psychotic symptoms | None for five weeks |
| Mood | PHQ-2 0 |
| Medicines | Aripiprazole 5 mg each morning; amlodipine 5 mg daily; naloxone nasal spray on hand |

## Health risk assessment

Completed on paper in the waiting room and reviewed with the patient by Dr. Achterberg-Cole. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than two months ago |
| Psychosocial | Weekly cognitive behavioral therapy; friends from boxing and the Army; worries about money less since meeting the social worker |
| Substance use | In treatment for cocaine use disorder; one day of use two weeks ago; AUDIT-C 3 at intake |
| Tobacco | Never smoked |
| Physical activity | Walks most days and does light bag work twice a week |
| Nutrition | Eats regular meals; cutting down on salt for his blood pressure |
| Sleep | Six to seven hours |
| Safety at home | Feels safe; no firearms in the home |
| Road safety | Wears a seat belt; does not drive after drinking or using |
| Activities of daily living | Independent |
| Hearing and vision | No difficulty |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, weight loss or night sweats |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | Cold resolved; no nosebleeds |
| Cardiovascular | Negative | No chest pain, palpitations or swelling of the ankles |
| Respiratory | Negative | No cough or shortness of breath |
| Gastrointestinal | Negative | No blood in the stool or change in bowel habit |
| Genitourinary | Negative | No urinary hesitancy or nocturia |
| Musculoskeletal | Negative | Stiff hands in the mornings for a few minutes only |
| Neurological | Negative | No headaches, weakness, numbness or memory lapses |
| Psychiatric | Negative | No persecutory fears; mood good; restlessness on aripiprazole denied; no thoughts of suicide or of harming anyone |

10 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with **S**
- Aripiprazole 5 mg oral tablet, one tablet each morning **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/84 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 29.2 kg/m². All vital signs are synthetic.

PSA: 1.3 ng/mL; PHQ-2: 0. All results are synthetic.

## Immunizations given today

- Influenza vaccine, standard dose, for the coming season **S**
- Tdap vaccine; last tetanus booster more than ten years ago **S**
- Pneumococcal conjugate vaccine (PCV20), recommended for all adults aged 50 and older **S**
- Hepatitis B vaccine (HepB-CpG), first of two doses; not immune at intake **S**
- Hepatitis A vaccine, adult, first of two doses, recommended for people who use drugs **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 102.0 kg, BMI 29.2; blood pressure 132/84; pulse 76 |
| Ears, nose, mouth, and throat | Nasal septum intact; hearing normal to whispered voice |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur; peripheral pulses normal |
| Respiratory | Clear to auscultation |
| Abdomen | Soft and non-tender; no pulsatile mass |
| Skin | No rash |
| Neurological | No tremor, rigidity or abnormal movements; gait normal |
| Psychiatric | Calm and engaged; no persecutory content |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. HIV, hepatitis C, hepatitis B and syphilis tests at intake were negative, and he is not immune to hepatitis B. Fasting lipids at the consultation: total cholesterol 204, HDL 44, LDL 128 and triglycerides 160 mg/dL; his 10-year cardiovascular risk by the PREVENT equations is about 6 percent, below the threshold for a statin, so he chose diet and activity with a repeat panel in a year. After shared decision-making about the higher prostate cancer risk in Black men and the trade-offs of testing, he chose a PSA test: 1.3 ng/mL. **S**
   - Stool immunochemical test kit given, to return within two weeks.
   - Repeat lipid panel in one year.
   - Next preventive visit in one year.
2. **Cocaine use disorder with cocaine-induced psychotic disorder, psychosis in remission** (F14.250). No psychotic symptoms for five weeks; one day of cocaine use two weeks ago, reported by him and met without blame. No akathisia or abnormal movements. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Continue aripiprazole 5 mg until the ten-week review, where a taper will be discussed.
   - Continue contingency management and weekly cognitive behavioral therapy.
3. **Hypertension on amlodipine** (I10). Clinic 132/84 and home average 132/84 mmHg: improving, not yet at target. **S**
   - Continue amlodipine 5 mg; review at ten weeks with the echocardiogram.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 132/84 mmHg on amlodipine |
| Colorectal cancer screening | Ordered | No screening he can recall; stool immunochemical test kit given today, with colonoscopy if positive |
| Prostate cancer screening | Completed today | Shared decision-making for men 55 to 69, including the higher risk in Black men; he chose a PSA test: 1.3 ng/mL |
| Lung cancer screening | Not indicated | Never smoked |
| Abdominal aortic aneurysm screening | Not indicated | Recommended for men 65 to 75 who have ever smoked; he is 55 and never smoked; his echocardiogram next week will measure the aortic root and ascending aorta |
| Lipid screening and cardiovascular risk | Up to date | Fasting lipids at the consultation; 10-year PREVENT risk about 6 percent; statin not indicated now; repeat in one year |
| Diabetes screening | Up to date | Hemoglobin A1c 5.5% at intake (BMI 29) |
| HIV screening | Up to date | Negative at intake |
| Hepatitis C screening | Up to date | Antibody negative at intake |
| Hepatitis B screening | Up to date | Triple panel at intake: not infected and not immune |
| Depression screening | Completed today | PHQ-2 0 |
| Unhealthy drug use | Up to date | In treatment for cocaine use disorder |
| Unhealthy alcohol use | Up to date | AUDIT-C 3 at intake; advised to keep alcohol low, since it often leads to cocaine use |
| Influenza vaccine | Completed today | Standard-dose vaccine for the coming season |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today |
| Pneumococcal vaccine | Completed today | PCV20 today; recommended for all adults 50 and older |
| Hepatitis B vaccine | Completed today | First of two HepB-CpG doses; second in one month or more |
| Hepatitis A vaccine | Completed today | First of two doses; drug use is an indication; second in six months |
| Recombinant zoster vaccine | Due | Recommended from 50; he chose to have it at his next visit rather than a sixth injection today |
| COVID-19 vaccine | Declined | Offered for the coming season; he will think about it |

## Advance care planning

Voluntary advance care planning discussion of about 18 minutes, with his consent. He named a health care agent and completed a health care proxy form; the agent is recorded in the chart and is not named here. He said that what matters most to him is being treated with respect, keeping his independence, and not becoming a burden to anyone. He would want treatment for any condition from which he could recover. He chose not to record other treatment preferences today. The plan will be revisited yearly or after any serious illness. **S**

## Guideline basis

- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2023), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine 2024;18(1S Suppl 1):1-56)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Ten-week review in one week with the echocardiogram. Stool test result by mail. Second hepatitis B dose in one month or more; second hepatitis A dose in six months; zoster vaccine at the next visit. Next preventive visit in one year. **S**
- Next scheduled visit 2026-09-21: ten-week review: remission, the antipsychotic taper, cognition off cocaine, the echocardiogram and a one-day return to use. **S**
